04:53 PM EDT, 10/24/2025 (MT Newswires) -- Mural Oncology ( MURA ) said its shareholders overwhelmingly approved the company's acquisition by XRA 5, a subsidiary of XOMA Royalty ( XOMA ) , for at least $36.2 million.

Mural shareholders will receive $2.035 a share, with the potential for up to an additional $0.205 a share depending on closing net cash.

The acquisition is expected to close this quarter, subject to customary conditions and approval from the High Court of Ireland, Mural said Friday in a statement.